Cargando…

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) displays heterogeneity in appearance—a distinctive pale clear to eosinophilic cytoplasm; however, little is known about the underlying mechanisms and clinical implications. We investigated the role of these eosinophilic features in ccRCC on oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Takashi, Ohe, Chisato, Ikeda, Junichi, Atsumi, Naho, Ohsugi, Haruyuki, Sugi, Motohiko, Higasa, Koichiro, Saito, Ryoichi, Tsuta, Koji, Matsuda, Tadashi, Kinoshita, Hidefumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477329/
https://www.ncbi.nlm.nih.gov/pubmed/34580162
http://dx.doi.org/10.1136/jitc-2021-002922
_version_ 1784575820416679936
author Yoshida, Takashi
Ohe, Chisato
Ikeda, Junichi
Atsumi, Naho
Ohsugi, Haruyuki
Sugi, Motohiko
Higasa, Koichiro
Saito, Ryoichi
Tsuta, Koji
Matsuda, Tadashi
Kinoshita, Hidefumi
author_facet Yoshida, Takashi
Ohe, Chisato
Ikeda, Junichi
Atsumi, Naho
Ohsugi, Haruyuki
Sugi, Motohiko
Higasa, Koichiro
Saito, Ryoichi
Tsuta, Koji
Matsuda, Tadashi
Kinoshita, Hidefumi
author_sort Yoshida, Takashi
collection PubMed
description BACKGROUND: Clear cell renal cell carcinoma (ccRCC) displays heterogeneity in appearance—a distinctive pale clear to eosinophilic cytoplasm; however, little is known about the underlying mechanisms and clinical implications. We investigated the role of these eosinophilic features in ccRCC on oncological outcomes and response to tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). METHODS: One-hundred and thirty-eight ccRCC cases undergoing radical surgery (cohort 1) and 54 metastatic ccRCC cases receiving either TKIs or ICIs (cohort 2) were included. After histological evaluation, all cases were divided into three phenotypes based on the eosinophilic features at the highest-grade area: clear, mixed, or eosinophilic type. Gene expression and immunohistochemical analyses were performed to explore the potential mechanisms of these phenotypes in cohort 1. Further, the association of the three phenotypes with the best objective response to TKI or ICI, clinical benefit (complete/partial response or stable disease), and overall survival (OS) was assessed in cohort 2. RESULTS: The clear type was significantly associated with increased hypoxia as well as angiogenesis gene signatures compared with the eosinophilic type. Gene signatures and protein expression related to effector T cell and immune checkpoint molecules were elevated to a greater extent in the eosinophilic type, followed by the mixed and clear types. The mixed and eosinophilic types exhibited greater PBRM1-negativity and increased prevalence of the epithelial-mesenchymal transition gene signature than the clear type. In the mixed/eosinophilic types of cohort 2, significant clinical benefit was observed in the ICI therapy group versus the TKI therapy group (p=0.035), and TKI therapy vs ICI therapy was an independent factor for worse prognosis of OS (HR 3.236; p=0.012). CONCLUSION: The histological phenotype based on the eosinophilic features, which are linked to major immunological mechanisms of ccRCC, was significantly correlated with therapeutic efficacy.
format Online
Article
Text
id pubmed-8477329
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84773292021-10-08 Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade Yoshida, Takashi Ohe, Chisato Ikeda, Junichi Atsumi, Naho Ohsugi, Haruyuki Sugi, Motohiko Higasa, Koichiro Saito, Ryoichi Tsuta, Koji Matsuda, Tadashi Kinoshita, Hidefumi J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Clear cell renal cell carcinoma (ccRCC) displays heterogeneity in appearance—a distinctive pale clear to eosinophilic cytoplasm; however, little is known about the underlying mechanisms and clinical implications. We investigated the role of these eosinophilic features in ccRCC on oncological outcomes and response to tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). METHODS: One-hundred and thirty-eight ccRCC cases undergoing radical surgery (cohort 1) and 54 metastatic ccRCC cases receiving either TKIs or ICIs (cohort 2) were included. After histological evaluation, all cases were divided into three phenotypes based on the eosinophilic features at the highest-grade area: clear, mixed, or eosinophilic type. Gene expression and immunohistochemical analyses were performed to explore the potential mechanisms of these phenotypes in cohort 1. Further, the association of the three phenotypes with the best objective response to TKI or ICI, clinical benefit (complete/partial response or stable disease), and overall survival (OS) was assessed in cohort 2. RESULTS: The clear type was significantly associated with increased hypoxia as well as angiogenesis gene signatures compared with the eosinophilic type. Gene signatures and protein expression related to effector T cell and immune checkpoint molecules were elevated to a greater extent in the eosinophilic type, followed by the mixed and clear types. The mixed and eosinophilic types exhibited greater PBRM1-negativity and increased prevalence of the epithelial-mesenchymal transition gene signature than the clear type. In the mixed/eosinophilic types of cohort 2, significant clinical benefit was observed in the ICI therapy group versus the TKI therapy group (p=0.035), and TKI therapy vs ICI therapy was an independent factor for worse prognosis of OS (HR 3.236; p=0.012). CONCLUSION: The histological phenotype based on the eosinophilic features, which are linked to major immunological mechanisms of ccRCC, was significantly correlated with therapeutic efficacy. BMJ Publishing Group 2021-09-27 /pmc/articles/PMC8477329/ /pubmed/34580162 http://dx.doi.org/10.1136/jitc-2021-002922 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical/Translational Cancer Immunotherapy
Yoshida, Takashi
Ohe, Chisato
Ikeda, Junichi
Atsumi, Naho
Ohsugi, Haruyuki
Sugi, Motohiko
Higasa, Koichiro
Saito, Ryoichi
Tsuta, Koji
Matsuda, Tadashi
Kinoshita, Hidefumi
Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
title Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
title_full Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
title_fullStr Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
title_full_unstemmed Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
title_short Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
title_sort eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477329/
https://www.ncbi.nlm.nih.gov/pubmed/34580162
http://dx.doi.org/10.1136/jitc-2021-002922
work_keys_str_mv AT yoshidatakashi eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT ohechisato eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT ikedajunichi eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT atsuminaho eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT ohsugiharuyuki eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT sugimotohiko eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT higasakoichiro eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT saitoryoichi eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT tsutakoji eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT matsudatadashi eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade
AT kinoshitahidefumi eosinophilicfeaturesinclearcellrenalcellcarcinomacorrelatewithoutcomesofimmunecheckpointandangiogenesisblockade